[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338587-105":59,"doc-detail-338587-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","screening-of-cancer-specific-biomarkers-for-hepatitis-b-related-hepatocellular-carcinoma-based-on-a-proteome-microarray","Screening of Cancer-Specific Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma Based on a Proteome Microarray","","This study investigates differential expression of autoantibodies against tumor-associated antigens in hepatitis B-related liver diseases. It identifies EID3, CNOT3, and UBE2E as potential cancer-specific biomarkers for early diagnosis of hepatitis B-related hepatocellular carcinoma (HCC). Screening and HCC-focused discovery used proteome microarrays, followed by ELISA validation. Results link UBE2Z, CNOT3, and EID3 to liver function indicators and support clinical application for distinguishing HBV-related HCC from other liver conditions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/screening-of-cancer-specific-biomarkers-for-hepatitis-b-related-hepatocellular-carcinoma-based-on-a-proteome-microarray/338587/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/screening-of-cancer-specific-biomarkers-for-hepatitis-b-related-hepatocellular-carcinoma-based-on-a-proteome-microarray/338587.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in hepatitis B-related HCC diagnosis?","Question",{"text":113,"@type":114},"Current diagnosis relies mainly on ultrasound and serum alpha-fetoprotein (AFP), which has low detection rates in early disease and limited ability to distinguish false positives from other liver diseases.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were candidate biomarkers identified in this research?",{"text":118,"@type":114},"The study screened differentially expressed autoantibodies against tumor-associated antigens using a large-scale multistage proteome microarray approach, followed by bioinformatics analysis.",{"name":120,"@type":111,"acceptedAnswer":121},"Which biomarkers were validated as potential cancer-specific markers?",{"text":122,"@type":114},"In the validation cohort, UBE2Z, CNOT3, and EID3 were correlated with liver function indicators in hepatitis B-related HCC, supporting their role as cancer-specific biomarkers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338587,1790784486,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Screening of Cancer-Speciﬁc Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma Based on a Proteome Microarray  \nAuthors  \nWudi Hao, Danyang Zhao, Yuan Meng, Mei Yang, Meichen Ma, Jingwen Hu, Jianhua Liu, and Xiaosong Qin  \nCorrespondence [liujh@sj-hospital.org](liujh@sj-hospital.org) ; qinxs@sj[hospital.org](hospital.org)  \nIn Brief  \nThis study investigates the differential expression of autoantibodies against tumorassociated antigens in hepatitis B-related liver diseases. Our ﬁndings highlighted EID3, CNOT3, and UBE2E as potential cancer-speciﬁc biomarkers for the early diagnosis of hepatitis B-related HCC, which provide ascientiﬁc basis for the clinical management of HCC.  \nGraphical Abstract  \nHighlights  \n• Hepatitis B (HBV)-related hepatocellular carcinoma (HCC) biomarkers were screened.  \n• Novel cancer-speciﬁc biomarkers were identiﬁed using proteome microarrays.  \n• UBE2Z, CNOT3, and EID3 correlated with liver function indicators.  \n• These biomarkers are potential cancer-speciﬁc markers for primary HBV-related HCC.  \n2024, Mol Cell Proteomics 23(12), 100872  \n© 2024 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY-NC-ND license ([http://](http://)[ ](http://)[creativecommons.org/licenses/by-nc-nd/4.0/](creativecommons.org/licenses/by-nc-nd/4.0/)).  \n[https://doi.org/10.1016/j.mcpro.2024.100872](https://doi.org/10.1016/j.mcpro.2024.100872)  \n RESEARCH  \n| Screening of Cancer-Speciﬁc Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma Based on a Proteome Microarray\u003Cbr>Wudi Hao 1 ,2, Danyang Zhao 1 ,2, Yuan Meng 1 ,2, Mei Yang 1 ,2 , Meichen Ma 1 ,2 , Jingwen Hu 1 ,2, Jianhua Liu 1 ,2 ,* , and Xiaosong Qin 1 ,2 ,* |  |\n| --- | --- |\n| Hepatocellular carcinoma (HCC) is associated with one of the highest mortality rates among cancers, rendering its early diagnosis clinically invaluable. Serum biomarkers, speciﬁcally alpha-fetoprotein (AFP), represent the most promising and widely used diagnostic biomarkers for HCC. However, its detection rate is low in the early stages of HCC progression, and distinguishing speciﬁc false positives for other liver-related diseases, such as cirrhosis and acute hepatitis, remains challenging. Therefore, this study was conducted to identify biomarkers for hepatitis B (HBV)-related liver diseases by screening differentially expressed autoantibodies against tumor-associated antigens (TAAbs). We designed a large-scale multistage investigation, encompassing initial screening, HCCfocused, and ELISA validation cohorts to identify potential TAAbs in HBV-related liver diseases, spanning from healthy control (HC) individuals to patients with chronic hepatitis B (CHB), hepatitis B-related cirrhosis (HBC), and HCC, using protein microarray technology. The differential biological characteristics of TAAbs were analyzed using bioinformatics analysis. Validation of tumor-speciﬁc biomarkers for HCC was performed using ELISA. In the screening cohort, 547 candidate TAAbs were identiﬁed in the HCC group compared to those in the HC group. In the HCC-focused cohort, 64, 61, and 65 candidate TAAbs were identiﬁed in the CHB, HBC, and HCC groups, respectively, compared to those in the HC group. Thirtyfour proteins exhibited continuously elevated expression from HCs to patients with CHB, HBC, and HCC. Among these, nine were identiﬁed as cancer-speciﬁc proteins. In the validation cohort, UBE2Z, CNOT3, and EID3 were correlated with liver function indicators in patients with hepatitis B-related HCC. Overall, UBE2Z, CNOT3, and EID3 emerged as cancer-speciﬁc biomarkers for HBVrelated liver disease, providing a scientiﬁc basis for clinical application.\u003Cbr>Hepatocellular carcinoma (HCC) ranks sixth among prevalent cancers and has one of the highest mortality rates (1) . Research has demonstrated an annual increase in the | mortality rate of HCC by approximately 2% to 3%, primarily attributed to late di","cbCaiogfjbu8GrK2","https://ap.wps.com/l/cbCaiogfjbu8GrK2","pdf",5578936,15,"English","# Introduction\n## Background and clinical need for early diagnosis\n## Proteome microarrays and antibody-based biomarker identification\n# Methods\n## Multistage screening and HCC-focused cohorts\n## ELISA validation of tumor-specific biomarkers\n# Results\n## Differentially expressed autoantibodies across disease groups\n## Candidate biomarker identification and correlation analyses\n# Conclusion","[{\"question\":\"What problem does the study address in hepatitis B-related HCC diagnosis?\",\"answer\":\"Current diagnosis relies mainly on ultrasound and serum alpha-fetoprotein (AFP), which has low detection rates in early disease and limited ability to distinguish false positives from other liver diseases.\"},{\"question\":\"How were candidate biomarkers identified in this research?\",\"answer\":\"The study screened differentially expressed autoantibodies against tumor-associated antigens using a large-scale multistage proteome microarray approach, followed by bioinformatics analysis.\"},{\"question\":\"Which biomarkers were validated as potential cancer-specific markers?\",\"answer\":\"In the validation cohort, UBE2Z, CNOT3, and EID3 were correlated with liver function indicators in hepatitis B-related HCC, supporting their role as cancer-specific biomarkers.\"}]","Screening of Cancer-Specific Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma Based on a Proteome Microarray | PDF",1790024368,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/365fc5484f3317770f635baefaf45129.webp",983,1296,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12d4017a70b468a43284568d08754321.webp",982,1294,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bcd4e8c7e5acc086e41d3f8293b42ee.webp",981,1293,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e39b878fbebda61f42bb684a8df1217b.webp",980,1292]